Frantic demand for drugs to treat obesity from Novo Nordisk, Eli Lilly, and others could support a global market worth an eye-watering $60 billion within the next decade,
AstraZeneca is looking at spinning out its Chinese operation and listing it in Hong Kong or Shanghai to insulate the business from rising geopolitical tension, according t
Sandoz is a major player in biosimilar medicines, so it’s no surprise that it is concerned about how slowly these drugs are making inroads against their brand-name equival
It’s a case of so far, so good for Ipsen with its recent acquisition of Albireo, after the main asset in the deal – Bylvay – secured FDA approval for its second rare disea